Kyverna Therapeutics, Inc.
KYTX
$8.17
$0.091.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 3.82% | -7.55% | -26.54% | -45.49% | -108.36% |
| Total Depreciation and Amortization | -26.63% | -23.37% | -15.66% | -1.87% | 44.98% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 187.84% | 308.46% | 112.30% | 12.11% | 34.04% |
| Change in Net Operating Assets | -264.74% | -157.06% | -113.69% | -131.43% | 216.57% |
| Cash from Operations | -12.26% | -12.54% | -34.54% | -64.22% | -78.11% |
| Capital Expenditure | 53.92% | 99.70% | 99.77% | 73.19% | 66.51% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -113.14% | 48.58% | 125.17% | 155.61% | 141.52% |
| Cash from Investing | -113.61% | 51.41% | 124.87% | 154.61% | 130.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 64.65% | 48.12% | 15.48% | -4.53% | -59.18% |
| Issuance of Common Stock | 97,720.00% | 59,564.14% | -65.47% | -99.51% | -99.96% |
| Repurchase of Common Stock | -821.57% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 51.21% | 2.90% | 85.87% | 91.51% | 91.51% |
| Cash from Financing | 10,304.06% | 10,580.07% | -58.12% | -99.94% | -100.39% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 72.34% | 85.26% | -55.66% | -186.31% | -200.00% |